 
CONFIDENTIAL INFORMATION  CLINICAL STUDY PROTOCOL  
 
An Open -Label Study to Evaluate the Effect of the Administration of FX006 on Synovial 
Inflammation in Patients with Osteoarthritis of the Knee  
 
PROTOCOL NUMBER:    FX006- 2017- [ADDRESS_746654] Number:  2018- 000529- 30 
 
UTN NUMBER:  U1111- 1214- 3078  
 
PHASE:    3b 
 
STUDY MEDICATION(S):  FX006  
 
INDICATION:    Osteoarthritis of the knee  
  
MEDICAL MONITOR:   Scott Kelley, MD  
 Chief Medical Officer  
 Flexion Therapeutics  
Tel: 781- 305-7142  
 
  
SPONSOR:    Flexion Therapeutics  
 [ADDRESS_746655] 
 Burlington, MA [ZIP_CODE]  
 Tel: 781- 305-7777  
 
DATE:    12 Jul y2019  
VERSION:   6.0 
 
 
SUPERCEDES:  Version 5.0 
 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746656]/Ethics Committee  ...........................................................[ADDRESS_746657]:  FX006  ................................................................17  
5.2.2.  Rationale for FX006 in OA of the Knee  .....................................................................18  
5.2.3.  Toxicology  ..................................................................................................................18  
5.2.4.  Systemic and Local Pharmacokinetics (PK) in Patients with Osteoarthritis of 
the Knee  ......................................................................................................................19  
5.2.5.  Pharmacodynamics (PD) in Patients with Osteoarthritis of the Knee  ........................19  
5.2.6.  Efficacy in Patients with Osteoarthritis of the Knee  ..................................................19  
5.2.7.  Systemic and Local Safety in Patients with Osteoarthritis of the Knee  .....................20  
5.2.8.  Conclusion ..................................................................................................................21  
6. STUDY OBJECTIVES  ..............................................................................................22  
6.1. Primary O bjective  .......................................................................................................22  
6.2. Secondary Objectives  .................................................................................................22  
6.3. Exploratory Objectives  ...............................................................................................22  
7. INVESTIGATIONAL PLAN  .....................................................................................23  
7.1. Overall Study Design and Plan  ...................................................................................23  
7.2. Site Staffing Requirements  .........................................................................................23  
7.3. Discussion of Study Design  ........................................................................................24  
7.3.1.  Rationale for Study Population ...................................................................................24  
7.3.2.  Rationale for Dose Selection  ......................................................................................24  
7.3.3.  Rationale for Study Design  .........................................................................................24  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 4 of 54  7.3.4.  Rationale for Study Parameters  ..................................................................................24  
7.3.5.  Rationale for Control Type  .........................................................................................25  
7.4. Selection of Study Population ....................................................................................25  
7.4.1.  Number of Patients  .....................................................................................................25  
7.4.2.  Inclusion Criteria  ........................................................................................................25  
7.4.3.  Exclusion Criteria  .......................................................................................................26  
7.4.4.  Screen Failures  ............................................................................................................28  
7.5. Treat ment Administered  .............................................................................................28  
7.5.1.  Study Medication Treatment Arm(s)  ..........................................................................[ADDRESS_746658](s)  .........................................................................28  
7.5.3.  Receipt, Preparation, Dispensing, and Storage  ...........................................................29  
7.5.4.  Packaging and Labeling of Study Medication ............................................................29  
7.5.5.  Return of Study Medication ........................................................................................29  
7.5.6.  Method of Assigning Patients to Treatment Groups  ..................................................29  
7.5.7.  Blinding ......................................................................................................................29  
7.5.8.  Study Drug Administration Procedure  .......................................................................29  
7.5.9.  Treatment Compliance  ................................................................................................31  
7.5.10.  Removal of Patients from Therapy or Assessments  ...................................................31  
7.6. Prior and Concomitant Medications and Therapi[INVESTIGATOR_014]  ....................................................31  
7.6.1.  Allowable Medications and Therapi[INVESTIGATOR_014]  .......................................................................32  
7.6.2.  Restricted Medications  ...............................................................................................32  
7.7. Study Variables  ...........................................................................................................32  
7.7.1.  Safet y Variables  ..........................................................................................................32  
7.7.2.  Imaging Variables  .......................................................................................................32  
7.7.3.  Efficacy Variables  ......................................................................................................32  
7.7.4.  Biomarker Variables  ...................................................................................................33  
7.8. Schedule of Study Assessments ..................................................................................33  
7.9. Study Procedures  ........................................................................................................35  
7.9.1.  Informed Consent  .......................................................................................................35  
7.9.2.  Review of Eligibility, Medical History, Prior Treatment, and Medications  ..............35  
7.9.3.  Physical Examination  .................................................................................................35  
7.9.4.  Index Knee X -ray .......................................................................................................35  
7.9.5.  Index Knee Ultrasound  ...............................................................................................36  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 5 of 54  [IP_ADDRESS].  Machine Capabilities  ..................................................................................................36  
[IP_ADDRESS].  Scanning  Method ........................................................................................................36  
[IP_ADDRESS].  Image Capture  .............................................................................................................[ADDRESS_746659]  ...................................................................................36  
7.9.7.  Index Knee Assessment  ..............................................................................................37  
7.9.8.  12-lead ECG  ...............................................................................................................37  
7.9.9.  Vital Signs  ..................................................................................................................37  
7.9.10.  Height, Weight, and BMI Determination  ...................................................................37  
7.9.11.  Synovial Fluid Aspi[INVESTIGATOR_1516]  ...........................................................................................38  
7.9.12.  Central Clinical Laboratory Evaluations  ....................................................................38  
7.9.13.  Patient Questionnaires  ................................................................................................39  
7.9.14.  Treatment Administration  ...........................................................................................39  
7.9.15.  Review of Adverse Events and Concomitant Medications  ........................................40  
8. ADVERSE EVENTS ..................................................................................................41  
8.1. Definitions  ..................................................................................................................41  
8.2. Monitoring of Adverse Events  ....................................................................................42  
8.2.1.  Monitoring of Laboratory Assessments and other Diagnostic Tests  ..........................42  
8.3. Assessment of Adverse Events  ...................................................................................42  
8.3.1.  Assessment of Severity  ...............................................................................................42  
8.3.2.  Assessment of Relationship to Study Medicatio n ......................................................43  
8.4. Recording of Adverse Events  .....................................................................................43  
8.4.1.  Reporting of Serious Adverse Events  .........................................................................43  
8.4.2.  Safety Monitoring Roles  .............................................................................................44  
8.4.3.  Clinical Management of Index Knee Related Events  .................................................44  
8.4.4.  Pregnancy  ...................................................................................................................45  
9. STATISTICAL C ONSIDERATIONS  .......................................................................46  
9.1. Statistical and Analytical Plans  ..................................................................................46  
9.1.1.  Interim Analysis  ..........................................................................................................46  
9.1.2.  Final Analyses  ............................................................................................................46  
9.2. General Considerations and Methods  .........................................................................46  
9.2.1.  Analysis Populations  ..................................................................................................46  
9.2.2.  Study Data  ..................................................................................................................47  
9.2.3.  Study Var iables for Assessment  .................................................................................47  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 6 of 54  9.2.4.  Sub- Groups and Covariates  ........................................................................................47  
9.3. Determination of Sample Size  ....................................................................................47  
9.4. General Statistical Methods  ........................................................................................47  
9.4.1.  Demographics and Baseline Characteristics  ...............................................................47  
9.4.2.  Exposure  .....................................................................................................................47  
9.4.3.  Efficacy Analyses  .......................................................................................................47  
9.4.4.  Safety Analyses  ..........................................................................................................48  
[IP_ADDRESS].  Analysis of Adverse Events  ........................................................................................48  
[IP_ADDRESS].  Other Safety Analyses  ................................................................................................48  
10. DATA QUALITY ASSURANCE  ..............................................................................49  
11. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  .......................................................50  
11.1.  Case Report Forms  .....................................................................................................50  
11.2.  Study Medication Accountability  ...............................................................................50  
11.3.  Confidentiality of Data  ...............................................................................................50  
11.4.  Retention of Records  ..................................................................................................50  
11.5.  Protocol Adherence  ....................................................................................................51  
12. PUBLICATION POLICY  ..........................................................................................52  
12.1.  Sponsor’s Publication Policy  ......................................................................................[ADDRESS_746660] OF TABLES  
Table 1:  Schedule of Study Assessments ..................................................................................34  
Table 2:  BMI Calculations  ........................................................................................................38  
Table 3:  Clinical Laboratory Panel  ...........................................................................................39  
 
 
 
  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746661]  
HIV Human Immunodeficiency Virus  
HPA  Hypothalamic -pi[INVESTIGATOR_2117] -adrenal  
IA Intra-articular  
IB Investigator’s Brochure  
IL-1β Interleukin 1 beta  
IRB/EC  Institutional Review Board/Ethics Committee  
IM Intramuscular  
IV Intravenous  
JSN Joint Space Narrowing  
kg Kilogram  
KOOS  Knee injury and Osteoarthritis Outcome Score  
LK Likert  
LSM  Least Square Mean  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
mL Milliliter  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 8 of 54  mm Millimeter  
MRI  Magnetic Resonance Imaging  
mRNA  Messenger Ribonucleic Acid (RNA)  
msec  Millisecond  
NaCl  Sodium Chloride  
OA Osteoarthritis  
OARSI  Osteoarthritis Research Society International  
PD Pharmacodynamic (s) 
PGIC  Patients’ Global Impression of Change  
PI [INVESTIGATOR_569504][lactic -co-glycolic acid]  
PK Pharmacokinetic (s) 
PRP Platelet Rich Plasma  
QOL  Quality of Life  
QTc QT interval corrected for heart rate  
RBC  Red Blood Cells 
RNA  Ribonucleic Acid  
SAE  Serious Adverse Event 
SAP Statistical Analysis Plan 
TEAE  Treatment -emergent Adverse Event 
TA1 Triamcinolone Acetonide  
TAcs2 Triamcinolone Acetonide Injectable Suspension, Immediate -Release 
(commercially available)  
US [LOCATION_002]  of America  
USP [LOCATION_002] Pharmacopeia  
w/w weight  by [CONTACT_538725]  
                                                 
[ADDRESS_746662] protocols and documents as TCA -IR 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 9 of 54  2. SYNOPSIS  
Title of Study: An Open -Label Study to Evaluate  the Effect of the Administration of FX006 on Synovial 
Inflammation in Patients with O steoarthritis  of the Knee  
Study Centers:   Approximately  10 centers  
Study Phase:   3b 
Objectives : 
The primary objective of this study is to assess the effect of a single intra -articular (IA) injection of FX006 32 
milligram s (mg) to control inflammation as measured by a reduction in Magnetic Resonance Imaging ( MRI ) 
assessed synovial volume in patients with symptomatic osteoarthritis (OA) of the knee  and defined synovi al volume 
at baseline . 
Secondary objectives of the study include the following:  
• To assess the effect of FX006 on pain , stiffness, function and quality of life  
• To assess changes in bone  area and cartilage  thickness of the knee  
Exploratory objectives of the study include the following:  
• To assess structural changes in bone, cartilage and  meniscus   
• To assess changes in contrast enhancement of tissue other than synovial tiss ue  
• To identify Responders and Non -Responders by [CONTACT_569532], 
cartilage and other tissue s  
• Through assessment of blood IL -1b Messenger Ribonucleic Acid  (mRNA ) levels , to segment  patients into 
inflammatory and non- inflammatory phenotypes, and to examine the response to therapy of these 
phenotypes  
Study Design and Methodology : 
This is an open -label s tudy assessing the e ffect of the administration of a single IA injection of FX006 32 mg on 
synovial volume  in patients with OA of the knee.  The study will be conducted in male and female patients  who are 
≥ [ADDRESS_746663] of the index knee . For e ach MRI , a pretreatment  synovi al volume  measurement  will be 
derived  by [CONTACT_569533]. Patients w ill then receive a single IA injection of FX006 administered to the 
index knee at Baseline/Day [ADDRESS_746664] a blood sample drawn for Estimated Glomerular 
Filtration Rate (eGFR ) testing within 30 days prior to the scheduled MRIs.  In addition, a patient questionnaire will 
be administered and adverse events ( AEs) and concomitant medication updates will be collected via telephone at 
Weeks 12 and 18.  
The study is expected to enroll over approximately 15 months.  
Number of Patients : 
Approximately [ADDRESS_746665], Dose and Mode of Administration : 
FX006 – extended release formulation of triamcinolone acetonide ( TA) in 75:25 poly(lactic -co-glycolic) acid 
(PLGA) microspheres : Nominal 32 mg TA, IA injection, administered as a 5 milliliter  (mL) injection  
Reference Compound(s), Dose and Mode of Administration:  
Not applicable  
 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 10 of 54  Duration of Dosing:  
Single IA injection  of FX006 
Inclusion Criteria:  
To be included in the trial, patients must fulfill the following criteria:  
1. Written consent to participate in the study  
2. Male or female ≥ 40 years of age  
3. Body mass index (BMI) ≤  40 kg/m2 
4. Ambulatory and in good general health  
5. Willing and able to comply with the study procedures and visit schedules and able to follow verbal and 
written instructions  
6. Willing  to abstain from use of the following protocol -restricted medications during the study : 
a. Topi[INVESTIGATOR_569505] s (from 5 days  prior to  Pre-treatment MRI  through  Week 6  MRI , and again  
from 5 days prior to Week 24  MRI ) 
b. Intravenous (IV), intramuscular (IM) and oral corticosteroids (Note: inhaled, intranasal , and 
topi[INVESTIGATOR_569506]) 
c. IA corticosteroids in any joint other than the study medication  
d. Any IA intervention in the index knee including aspi[INVESTIGATOR_1516] o r the injection of any approved or 
investigational agent, including viscosupplementation (hyaluronic acid)  
e. Any investigational d rug, device , or biologic  
f. Immunomodulators, immunosuppressives, or chemotherapeutic agents  
g. Live or attenuated vaccines  
7. Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening (patient self -report is 
acceptable)  
8. Currently meets Ameri can College of Rheumatology (ACR) Criteria (clinical and radiological) for OA 
(Altman et al, 19 86) as follows:  
a. Knee pain  
b. at least 1 of the following:  
i. Age > 50 years  
ii. Stiffness < 30 minutes  
iii. Crepi[INVESTIGATOR_72831]  
c. Osteophytes  (as determined by [CONTACT_569534] X -ray obtained at Screening )  
9. Kellgren -Lawrence (K -L) Grade 2 or 3 in the index knee based on X -ray performed during Screening 
(centrally  read)  
a. Grade 2: definite osteophytes and possible narrowing of joint space  
b. Grade 3: moderate multiple osteophytes, definite narrowing of joint space and some sclerosis and 
possible deformity of bone ends  
10. Western Ontario and McMaster Universities Osteoarthritis Index  (WOMAC A)  total sum score of ≥ 6 at 
Screening and Baseline/Day [ADDRESS_746666] month (as reported by [CONTACT_102]).  
12. If bilateral OA exists, pain in the contralateral knee must be less than pain in the index knee as reported by 
[CONTACT_102]; if pain is equal, index kn ee will be identified based on knee with highest level of inflammation 
as determined by [CONTACT_2207]  
13. Sexually active males and females of child -bearing potential (defined as not surgically sterile or post-
menopausal [defined as 12 consecutive months with no menses without an alternative medical cause] for at 
least 1 year as documented in medical history) agree to use one of the following highly effective method s 
of contraception: abstinence; oral, injected or implanted hormonal methods of contraception; intra uterine 
device or intrauterine system; condom or occlusive cap (diaphragm or cervical/vault caps) with 
spermicidal foam/gel/film/cream/suppository; or monogamous intercourse with a partner who is surgically 
sterile (post- vasectomy, post -hysterectomy, or tu bal ligation) . Such contraceptive measures should be used 
throughout the duration of the study.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 11 of 54  Exclusion Criteria:  
Patients fulfilling at least one of the following criteria may not be included in the study:  
Disease -related criteria  
1. Any inflammatory arthritis including r eactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis, arthritis associated with inflammatory bowel disease , gout or secondary OA from gout  
2. History of infection  or crystal disease  in the inde x knee joint   
3. Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of Screening  
 
Previous or concomitant treatment- related criteria  
4. Presence of surgical hardware or other foreign body in the index knee 
5. Surgery or  arthrosco py of the  index knee within 12 months of Screening  
6. IA corticosteroid (investigational or marketed ) in any joint  within 3 months of Screening  
7. IA treatment of the index knee with hyaluronic acid (investigational or marketed) within 6 months of 
Screening   
8. IV or IM corticosteroids (investigational or marketed) within 3 months of Screening  
9. Oral corticosteroids (investigational or marketed) within 1 month of Screening  
10. Any other IA drug/biologic in the index knee  within 6 months of Screening or 5 half -lives (whic hever is 
longer) (e.g., platelet rich plasma (PRP) injection, stem cells, p rolothera py, and amniotic fluid injection)  
11. Prior administration of FX006 ( Zilretta®) 
12. Planned/anticipated surgery of the index knee during the study period  
 
Patient- related criteria  
13. Suspected  hypersensitivity to any form of triamcinolone  
14. History of sarcoidosis or amyloidosis  
15. Active or history of malignancy within the last 5 years, with the exception of  resected basal cell 
carcinoma, squamous cell carcinoma of the skin, or effectively managed cervical carcinoma 
16. History or evidence of active or latent systemic fungal  or mycobacterial (including tuberculosis), or  of 
ocular herpes simplex  
17. Any bacterial or viral  infection requiring IV antibiotics within 4 weeks of Screening or oral antibiotics 
within 2 weeks of Screening  
18. History of osteomyelitis  in the index leg at any time, or of other areas within 5 years  
19. Laboratory evidence of infection with human immunodeficiency virus (HIV), positive test for hepatitis B 
surface antigen (HbsAg) or positive serology for hepatitis C virus  (HCV) with positive test for HCV 
Ribonucleic Acid (RNA)  
20. Any electrocardiogram (ECG) abnormality judged clinically significant by [CONTACT_14520].  
21. A medical history suggesting the p atient will or is likely to require a course of parenteral or oral 
corticosteroids during the study period  
22. eGFR results <  40 mL/minute  (reported as Creatin ine Clearance)  
23. Any contraindication to MRI Scanning  (e.g., presence of certain ferromagnetic foreign bodies or electronic 
devices including most cardiac pacemakers, claustrophobia)  
24. Known hypersensitivity to any form of MRI contrast  
25. History of or active Cushing’s syndrome  
26. Active substance abuse (drugs or alcoho l), or history of substance abuse within [ADDRESS_746667] 
28. Females  who are pregnant or nursing or plan to become pregnant during the study; men who plan to 
conceive during the study  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 12 of 54  29. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 5 years of Screening 
30. Has received a live or live attenuated vaccine within 3 months of Screening  
31. Use of any other investigational drug, biologic  or device within 3 months of Scr eening  
32. Any other clinically significant acute or chronic medical conditions (e.g., bleeding disorder) that, in the 
judgment of the Investigator, would preclude the use of an IA corticosteroid or that could compromise  
patient safety, limit the patient’s ability to complete the study, and/or compromise the objectives of the 
study  
Procedures and Assessments:  
The study will involve a  Screening period ( up to 28 days), a pretreatment day when an  Ultrasound  and MRI of the 
index knee will be performed , dosing at Baseline/Day [ADDRESS_746668] a blood sample drawn for eGFR testing within 30 days prior to the scheduled 
MRIs.  Follow -up via telephone will occur at Week s 12 and 18.   
At specified times throughout the study, patients will undergo physical examinations, index knee assessments , 
imaging of the index knee (MRI with contrast) , 12-lead ECG ; blood samples will be collected for laboratory safety 
tests and vital signs will be c ollected or measured.  Information regarding AEs and concomitant medications will be 
collected , and patient questionnaires ( Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index 
Likert (LK) 3.1 , the Knee injury and Osteoarthritis Outcome Score (KOOS) Quality of Life (QOL) Subscale ), and a 
set of questions exploring pain and stiffness  of the knee will be completed . 
Patients will have index knee synovial fluid collected at Baseline/Day 1 . These samples  will be preserved for 
potential future OA biomarker an alyses . 
Refer to Schedule of Study Assessments for full details.  
Blinding:  
Not applicable ; this is an open -label study.  
Study Drug  Administration Procedure:  
IA injections will be performed by [CONTACT_941] a ssigned injector.  The injector may choose the position of the knee ( e.g., 
extended or flexed), the approach for the injection ( e.g., medial or lateral) and the numbing agent to be used (e.g., 
ethyl chloride, subcutaneous lidocaine; IA anesthetics are not allowed) based on standard of care. Sterile technique 
should be used.   
Prior to injection, the index knee should be thoroughly cleansed using a bactericidal solution.  The index knee will 
be aspi[INVESTIGATOR_569507].  Following attempted aspi[INVESTIGATOR_1516], [ADDRESS_746669] related issues relating to reconstitution or administration of 
FX006 (e.g. inability to achieve an appropriate suspension, inability to administer the full dose due to clogging of 
the needle) and report the occurrence to the Site Monitor, as detailed in the Pharmacy Binder.  
Post-Injection Care  
Patients should be advised to avoid strenuous activities or prolonged weight -bearing activities for approximately [ADDRESS_746670] to physical activity throughout 
the duration of the study.  
If the patient has an immediate reaction (e.g., tenderness, increased pain, swelling, effusion, decreased mobility of 
the index joint), the patient should be treated according to local clinical guidelines and physician experience.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 13 of 54  Concomitant Medications:  
The exclusion criteria indicate that a patient may not be enrolled if he/she has used any of the following  within the 
specified windows. In addition , these medications should not be taken or u sed throughout the study:  
• IV, IM , or oral corticosteroids   
• IA corticosteroids in any joint  
• Any IA intervention in index knee including aspi[INVESTIGATOR_569508], including viscosupplementation (hyaluronic acid) .  
• Any investigational drug, device , or biologic  
• Immunomodulators, immunosuppressives, or chemotherapeutic agents  
• Live or attenuated vaccines  
• If patient is currently using other analgesics for pain relief, continued use is permitted; however , patient 
must abstain fro m use of topi[INVESTIGATOR_569505] s from 5 days  prior to  Pre-treatment MRI  through Week 6, 
and again  from 5 days prior to  Week 24  MRI . 
Criteria for Evaluation:  
Imaging Variables  
Synovial volume and structural changes in various tissues (bone, cartilage, meniscus) and c hange in contrast 
enhancement of tissues other than synovium  will be evaluated  based on MRI  by a central imaging vendor . 
 
Efficacy Variables  
Efficacy will be evaluated based on the results of the WOMACLK 3.1, 5 -point scale): pain, stiffness and function 
domains independently and collectively ( Bellamy et al,  1988 ), the KOOS QOL  and a set of questions exploring 
pain and stiffness  of the knee .  
 
Safety  Variables  
Safety and tolerability will be evaluated on the basis of  AEs spontaneously reported by [CONTACT_569535]: physical examinations, index knee assessments, vital 
signs, and clinical laboratory evaluations.   
 
Biomarker Variables  
Synovial fluid samples will be preserved for a maximum of 5 years for potential future analyses of biomarkers that 
may contribute to the pathogenesis of OA and/or be associated with responsiveness to FX006 treatment. No 
genomic analyses (gene sequencing studies) will be performed using these samples. Patients will be able to 
withdraw consent throughout the duration of storage. Once analysis has begun, consent will no longer be able to be 
withdrawn.  
Whole blood samples will be taken from patients at Baseline/Day 1 .  Total Ribonucleic Acid ( RNA ) will be isolated 
from these samples for analysis of messenger RNA (mRNA) levels of the pro -inflammatory cytokine i nterleukin 1 
beta (IL-1β).  The expression of baseline IL -1β among patients will be compared to several other parameter s, such 
as Index Knee X -rays and MRI images, with the goal of determining if baseline mRNA IL -1β expression 
contributes to the pathogenesis of OA and/or is  associated with responsiveness to FX006 treatment.  
Sample Size Considerations:  
Approximately  100 patients  will be enrolled to ensure a minimum of 70 evaluable Synovitis Imaging patients, as 
defined by [CONTACT_094] -treatment MRI synovi al volume  measurement of greater than 3000 mm3 of gadolinium enhancement 
as determined by [CONTACT_569533], with quality Pretreatment and Week 6 MRI s. Previous trials had 
similar sample sizes  (Gait et al, 2016)  (O’Neill et al. , 2016 ).  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 14 of 54  Statistical Methods: 
Complete details of the statistical analyses will be specified in the statistical analysis plan (SAP). Four  analysis 
populations are planned for the study  as follows:  
•  The Safety Population will include all patients  who receive study drug.  The Safety Population will be used 
to assess safety and tolerability.  
• The Synovitis Imaging Population will include all patients from the Safety Population who have a pre -
treatment  synovi al volume  measurement of greater than [ADDRESS_746671] no major protocol deviations and/or imaging variations 
(i.e. change in coil, machine, or software) deem ed to potentially impact the imaging analysis.   
• The Imaging Population will include all patients  from the Safety Population, who have quality MRI data 
available for pre -treatment and at least one post - baseline timepoint and with no major protocol deviations 
and/or imaging variations (i.e. change in coil, machine or software) deemed to potentially impact the 
imaging analysis.   
• The Efficacy Population will include all patients  from the Safety Population, who have at least one post - 
Baseline/Day 1 WOMAC or KOOS assessment.   
Demographic and baseline characteristics will be listed by [CONTACT_569536] .  
Frequencies and proportions will be presented for the categorical variables and descriptive statistics will be 
presented for continuous variables.  
Primary efficacy analysis  will be the m ean standardized change from baseline at 6 weeks in synovial volume will be 
determined and the 95% confidence interval  (CI) will be calculated. Secondary efficacy analyses  include an 
absolute cha nge (mm3) from baseline at 6 weeks in synovial volume will also be calculated and the 95% CI  will be 
presented. Standardized and absolute change from baseline will also be analyzed for synovial volume at 24 weeks.    
Descriptive statistics and the 95% CIs will be calculated on pain, stiffness,  function and quality of life. Other 
efficacy variables such as structural and contrast changes in bone, cartilage and other tissues based on the MRI 
results will be provided in the SAP and described in the Imaging Manu al.  A responder/non -responder analysis will 
be conducted to describe associations between physiological and functional/QOL measures and MRI results  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary.  Incidences 
(number and percent) of treatment -emergent adverse events (TEAEs), those events that started after dosing or 
worsened after dosing, will be presented.  Additional analyses of incidences of TEAEs will also be presented by 
[CONTACT_569537].  
Similar presentations will be provided for serious AEs, AEs leading to death, AEs leading to withdrawal from the 
study, and for AEs related to the index knee .  
Clinical laboratory data and vital sign information will be summarized as summary statistics for value and change 
from Day [ADDRESS_746672] deviation, 
minimum, and maximum.  
 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746673] /Ethics Committee   
This study will be conducted in compliance with current Good Clinical Practices (GCP) , and in 
accordance with local laws and reg ulations.  
This study protocol and other related study documents will be submitted to the Institutional 
Review Board/Ethics Committee ( IRB/EC ) by [CONTACT_569538]. IRB/EC approval must be obta ined before commencement of any 
study procedures. The study will be conducted only at sites where IRB/EC approval has been 
obtained. 
3.2. Ethical Conduct of Study  
This study will be conducted in accordance with the protocol, GCP guidelines and applicable 
national regulatory requirements.  
GCP is an international ethical and scientific quality standard for designing, conducting, 
recording, and reporting studies that involve the participation of human subjects. Compliance 
with this standard provides public assuranc e that the rights, safety, and well -being of study 
subjects are protected, consistent with the principles that have originated in the Declaration of 
Helsinki and that the clinical study data are credible.  
3.3. Patient  Information and Consent  
Prior to initiation  of any study related procedures, patients will give their written consent to 
participate in the study after having been informed about the nature and purpose of the study, 
participation and termination conditions, and risks and benefits.  
An IRB/EC -approve d informed consent document must be signed by [CONTACT_514909].  A copy of the informed consent document must be provided to the 
patient.  If applicable, it will be provided in a certified translation of the local la nguage.  
Signed informed consent forms must remain in each patient’s study file and must be available for 
verification by [CONTACT_9534].  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746674] UDY ADMINISTRATIVE 
STRUCTURE   
4.1. Investiga tors 
A Principal Investigator (PI) will be responsible for study conduct at each center and may 
delegate study -related activities to appropriately qualified and trained staff. This delegation will 
be documented in a study -specific Delegation of Responsibilities  form.  
The contact [CONTACT_569539] s participating in the trial will be kept in the Trial Master File.  
4.2. Study  Administrative  Structure  
The study will be managed by [CONTACT_569540]. 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 17 of 54  5. INTRODUCTION 
5.1. Osteoarthritis  
Osteoarthritis (OA) is a painful and debilitating musculoskeletal disease that is characterized by 
[CONTACT_90169]-articular (IA) inflammation, deterioration of  articular cartilage, and degenerative changes to 
peri-articular and subchondral bone ( Creamer and Hochberg, 1997; Goldring and Goldring, 
2006).  Arthritis is the most common cause of disability in the [LOCATION_002] of America ( US), 
and OA is the most common joint disease, affecting [ADDRESS_746675] that OA 
accounts for over $[ADDRESS_746676] large weight -bearing joints like the knees and hips, but also occurs in the 
shoulders, hands, feet and spi[INVESTIGATOR_050].  Patients with OA suffer from joint pain, tenderness, stiffness 
and limited movement.  As the disease progresses, it becomes increasingly painful and 
debilitating, culminating, in many cases, in the need for total joint arthroplasty.  
Current Guidelines from the American College of Rheumatology (ACR), Osteoarthritis Research 
Society International (OARSI) and the European League against Rheumatism (EULAR) 
recommend the use of IA corticosteroids for short -term acute pain relief  (Hochberg et al, 2012; 
Jordan et al, 2003;  Menge et al, 2014).  
While historically OA has been considered a non -inflammatory disease, it is increasingly being 
recognized that chronic synovitis occurs in all stages of knee OA ( Benito et al, 2005; Sellam and 
Berenbaum, 2010; Wenham and Conaghan, 2010). As  synovial inflammation is correlated with 
clinical symptoms and joint degeneration, it should be an important target for therapeutic 
intervention. The inflamed synovium may well be the target for IA corticosteroids which are 
widely used in knee OA ( Ayral et al, 2005).  
5.2. Background  
5.2.1. Investigational Medicinal Product:  FX006  
FX006 is an extended- release formulation of triamcinolone acetonide ( TA) for IA  
administration . It is approved in the US under the trade name [CONTACT_538774] ® (triamcinolone 
acetonide extended -release injectable suspension) for the management of pain of osteoarthritis of 
the knee .  FX006 is intended to deliver TA  to the synovial and peri -synovial tissues for a period 
of approximately 3 months depending on the dose administered ( Bodick et al, 2013) . 
FX006 contains TA , [LOCATION_002] Pharmacopeia (Ph. Eur/USP), formulated in 75:25 
poly( lactic -co-glycolic acid) (PLGA) microspheres with a nominal drug load of 25% ( weight by 
[CONTACT_8497] [ w/w] ) and is provided as a sterile white to  off-white powder for reconstitution. The drug 
product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium 
chloride (NaCl; 0.9% w/w), carboxymethylcellulose sodium (CMC; 0.5% w/w) and polysorbate -
80 (0.1% w/w) to form a suspension prior to IA injection.   
Further details of the physiochemical properties of FX006 can be found in the Investigator’s 
Brochure (IB).  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 18 of 54  5.2.2. Rationale for FX006 in OA of the Knee  
Available clinical and nonclinical data indicate that FX006  is safe and well tolerated when 
administered as a single injection into one knee and provide s pain relief that is meaningfully 
better and more persistent than that provided by t riamcinolone a cetonide i njectable s uspension, 
immediate -release (commercially available) ( TAcs ).  Nonclinical data and the literature suggest 
that this potential could extend to limiting structural progression in patients with inflammatory 
joint disorders. The near term clinical development program for FX006 focus es on analgesics 
effects in patient  with OA ( bilateral knee, hip, and shoulder) as well as other shoulder maladies.  
5.2.3. Toxicology 
Overall, single or repeat administration of FX006 at the proposed clinical dose of 32 mg has no 
new safety liabilities compared to T Acs: 
• Systemic findings were similar among T Acs and FX006 groups following single and repeat 
dosing and were generally  reversible.  Initial effects on clinical pathology parameters were 
more pronounced for the immediate -release form.  The incidence and/or intensity of steroid-
associated s ystemic histopathological findings at the later time points were slightly higher for 
high dose FX006 than for T Acs at the same dose level of TA (18.75 mg/m L/joint) , as 
expected based on the sustained release of TA .  Microspheres were not detected in tissue s 
outside of the synovial space.  
• Local findings were similar among the T Acs and the FX006 groups and were reversible.  The 
single and repeat dose dog toxicity studies recapi[INVESTIGATOR_569509], previously published, effects 
of TA in normal animal joints followin g prolonged exposure.  These include decreased 
Safranin O staining (single or repeat dose)  and changes in structure and cellularity of 
articular cartilage  (repeated dosing only) .   
• An expected, mild, reversible Foreign Body Response ( FBR ) was noted to the PLGA 
component of FX006 microspheres.  
− The local tissue response to the presence of blank microspheres as well as FX006 
microspheres consisted of an expected FBR of macrophage and multinucleated giant cell 
infiltration involving the synovium. Following a si ngle dose, the FBR was evident at Day 
4, peaked at approximately 6 weeks and was completely resolved by 6 months in all 
FX006- dosed animals. Occasional lymphocyte and plasma cell infiltrates and sporadic 
focal -to-multifocal areas of minimal- to-slight fibro sis resolved by 9 months.  Following 
repeat IA dosing, a similar local, reversible FBR was noted.   
− Further, the dogs in these studies showed no local signs of inflammation on or around the 
joint and did not display pain, discomfort or difficulty  in ambulation  in any treatment 
group; hence, this local response was considered to be nonadverse .  
Information available for TA from the literature, corticosteroid product labels and clinical 
experience suggest that the potential of genetic toxicity, reproductive toxicity and carcinogenic 
potential of TA are well understood.  Similarly, the biocompatibility and local safety of PLGA 
microspheres, and genotoxic, reproductive toxicological and carcinogenic potential of PLGA 
have been described in a combination of  literature and product information packages.  Therefore, 
no new risks relative to T Acs are presented by [CONTACT_538731]006 as intended for use.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 19 of 54  5.2.4. Systemic and Local Pharmacokinetics ( PK) in Patients with Osteoarthritis of the 
Knee  
Overall, FX006 displayed a favorable pl asma PK profile relative to that of TAcs. 
PK observations resulted in a controlled and stable release of TA  from PLGA  microspheres  into 
synovial tissues, where concentrations remained  high relative to plasma concentrations for at 
least [ADDRESS_746677] -dose, and slow elimination from the systemic circulation 
observed in the weeks thereafter .  
Relative to T Acs, 32 mg FX006 produced substantially lower peak plasma and systemic 
exposure to TA. FX006 performed as expected, prolonging the residence of TA in the joint while 
minimizing systemic exposure to TA.  
5.2.5. Pharmacodynamics (PD) in Patients with Osteoarthritis of the Knee  
In a Phase 2 PK/  PD study evaluating three dose levels of FX006 (10 mg, 40 mg, 60 mg) 
administered as a 3 mL injection , suppression of cortisol in the days following injection 
produced by [CONTACT_941] 10 and 40  mg dose of FX006 was less  than that produced by [CONTACT_82037] T Acs; 
the 60 mg dose of FX006 produced effects similar to 40 mg  TAcs. Cortisol suppression 
subsequent to Day 1- 2 associated with all doses of FX006 would not be expected to be of clinical 
consequence in adult patients without otherwi se compromised h ypothalamic -pi[INVESTIGATOR_2117] -adrenal  
(HPA)  axis function. 
In a Phase 2 study in diabetic patients with knee OA , treatment with 32 mg FX006 resulted in a 
statistically significant (p=0.0452) reduction in blood glucose elevat ion relative to T Acs over a 
72-hour period following IA injection. The time in glycemic target range (70 -180 mg/dL) 
(American Diabetes Association, 2016)  was greater for FX006 as compared to T Acs over t he 
[ADDRESS_746678] injection glucose monitoring period, blood 
glucose levels associated with FX006 remained at levels similar to  or lower than those produced 
by [CONTACT_538733]. This observation is consistent with PK studies demonstrating low systemic exposure to 
TA associated with FX006. 
5.2.6. Efficacy in Patients with Osteoarthritis of the Knee  
Efficacy data from three s tudies provide substantial  evidence supporting the effectiveness of 
32 mg FX006 in the management of OA pain. ( Bodick  et al,  2015;  Conaghan  et al,  2017)  
Results of the primary endpoint from the Phase 3, multi- center, adequate, and well -controlled 
trial, showed that patients treated with 32 mg FX006 had a rapid, durable, and meaningful 
analgesic response that was statistically significantly better than plac ebo treated patients 
(P<0.0001). This finding was supported by a second smaller Phase 2b study, where a highly 
similar pattern of response to 32 mg FX006 was demonstrated.  
Robustness of the primary outcome in the Phase 3 study  was further supported by [CONTACT_538734] 32 mg FX006  through secondary analyses utilizing the 
primary outcome data ( average daily pain  [ADP ]) to evaluate durability and magnitude of 
response. These included least square mean ( LSM ) testing at each week  and area under the effect 
curve ( AUE ) analyses for Weeks 1 through 12 and Weeks 1 through 24. Results demonstrated 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746679] Week 16. Responder analyses further suggested that FX006 provides 
clinically relevant improvement from Weeks 1 through 16 relative to placebo. 
Analyses utilizing data collected from other instruments or measures , i.e., Western Ontario and  
McMaster Universities Osteoarthritis Index (WOMAC ), Patients’ Global Impression of Change 
(PGIC ), Clinical Global Impression of Change ( CGIC ), and Knee injury and Osteoarthritis 
Outcome Score ( KOOS ) Quality of Life ( QOL ), provided additional insight into e ffects on pain 
relief as well as physical function and global well -being.  FX006 [ADDRESS_746680] antial evidence to support FX006 32 mg as an effective 
therapy for the management of OA knee pain.  
5.2.7. Systemic and Local Safety  in Patients with Osteoarthritis of the Knee  
The evaluation of 687 patients treated with a single IA injection of FX006 at any dose  in the 
FX006 clinical studies suggests that it was well tolerated with systemic and local safety profiles 
similar to those of T Acs and placebo.   
The safety data from the FX006 clinical studies are largely consistent.  
• The number of TEAEs reported was similar across groups (FX006 46.0 %; placebo 4 9.2% ; 
TAcs 51.0%).   
• The majority of TEAEs in FX006- treated patients were mild or moderate (Grade 1 or 2) . 
Severe or life- threatening events occurred in the FX006- treated patient s at a rate of 3.0% as 
compared to 5.0% and 2.6% in the placebo and T Acs groups, respectively .  
• In the FX006 -treated patients  (n=687) , the most common TEAEs were:  
− Arthralgia (in any joint) 9. 8% (n= 67) 
− Headache 5. 4% (n= 37) 
− Upper Respi[INVESTIGATOR_696] T ract I nfection 3.1% (n= 21) 
− Joint swelling 2.8% (n=19)  
− Contusion and back pain 2.3% (n=16)  
− Nasopharyngitis 2.2% (n=15)  
• The rate of serious adverse events (SAEs) was low and consistent across groups (FX006 
1.9%; placebo 1.1%; T Acs 2.3% ); none were considered related to the study drug.  
• Across all studies there were no deaths.   
In the Phase [ADDRESS_746681] 
injection included joint space narrowing (JSN), subchondral bone changes, osteonecrosis, and 
insuffici ency fracture.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 21 of 54  • The overall rate of JSN worsening of at least 1 -grade between baseline and Week 24 was low 
and similar among treatment groups (5.0% [7/140], 4.1% [6/148], and 3.5% [5/145] of 
patients with both baseline and Week 24 X -rays in the 32 mg FX006, placebo, and T Acs 
groups respectively); for all but 1 of these 18 patients, JSN worsened by 1- grade only. The 
remaining patient (in the placebo group) had a 2 -grade worsening in JSN (from 0 at baseline 
to Grade 2 at Week 24).  
• No FX006- treated patient had X -ray evidence of treatment -emergent insufficiency fracture, 
subchondral bone changes, or osteonecrosis at Week 24. 
• Eighteen patients discontinued the study prior to Week 24 and completed a final X -ray as 
part of early termination visit. Of these, 2 patients, 1 in the 32 mg FX006 group and 1 in the 
placebo group, had a 1- grade increase in JSN. There were no reports of i nsufficiency 
fracture, subchondral bone changes, or osteonecrosis . 
5.2.8. Conclusion  
These data provide bases for continued clinical stud y of FX006.   
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746682] of a single IA in jection of FX006 
32 mg  to control inflammation as measured by a reduction in MRI -assessed  synovial volume in 
patients with symptomatic  OA of the knee  and defined synovi al volume  at baseline.  
6.2. Secondary Objectives  
The secondary objectives of this study are : 
• to assess the effect of FX006 on pain, stiffness, function, and quality of life . 
• to assess changes in bone area and cartilage thickness of the knee.  
6.3. Exploratory Objectives  
The exploratory objectives of this study are : 
• to assess structural changes in bone,  cartilage , and meniscus . 
• to assess changes in contrast enhancement of tissue other than synovial tissue. 
• to identify Responders and Non -Responders by [CONTACT_569541], cartilage , and  other  tissue s.  
• through assessment of blood IL -1b mRNA levels , to segment  patients into inflammatory and 
non-inflammatory phenotypes, and to examine the response to therapy of these phenotypes . 
 
 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746683]  of the administration of a single IA injection of 
FX006 32 mg on synovial volume in patients with OA of the knee.  The study will be conducted 
in male and female patients who are ≥ [ADDRESS_746684] of the index knee . For each MRI, a pre-treatment  
synovi al volume  measurement will be derived  by [CONTACT_569533].  Patients will then 
receive a single IA injection of FX006 administered to the index knee at Baseline/Day [ADDRESS_746685] of the study at his/her site, ensuring that 
sufficient and appropriately experienced staff are available to conduct the trial , and ensuring that 
activities are appropriately delegated and documen ted.  Any delegation of responsibilities will be 
documented in a study -specific Clinical Site Resp onsibilities and Signature [CONTACT_26500].  The term 
‘Principal Investigator’ is used throughout this protocol to refer to the actual PI  [INVESTIGATOR_1238]/or his/her 
delegated team mem ber(s) for the specific responsibility being described.  
Pharmacist/ Coordinator  
• Must be a registered pharmacist or an individual with the qualifications and training required 
to handle and prepare study medications  
• Is responsible for handling and preparin g all study medications and maintaining 
investigational product accountability records  
Injector/Aspi[INVESTIGATOR_13521]   
• Must be a medical doctor, a physician’s assistant , or nurse practitioner e xperienced in 
administering IA injections and performing synovial fluid aspi[INVESTIGATOR_569510]  
• Is responsible for performing IA injections of study medication and synovial fluid aspi[INVESTIGATOR_569511]  
• Must be either the PI [INVESTIGATOR_11637]- investigator listed on the  FDA Form  1572  
• Must be a medical doctor, doctor of osteopat hic medicine, a physician’s assistant , or nurse 
practitioner  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 24 of 54  • Must have relevant OA experience  
• Is responsible for performing the physical examination and index knee  assessments   
• Can be responsible for assessing ultrasound images for the presence of synovitis  only if  a 
rheum atologist or orthopedic specialty   
• Is responsible for assessing all adverse event (AE) s including seriousness, severity, and 
causality  
Radiologist  
• Can be responsible for assessing ul trasound images for the presence of synovitis  only if a 
medical doctor specializing in radiology  
− Must be either the PI [INVESTIGATOR_175681] -investigator  
Imaging Technician  
• Must be an experienced technician in performing required imaging 
• Is responsible for per forming the required imaging  
The same individual may serve in multiple roles (e.g., a physician sub- investigator may serve as 
both the Injector and/or Assessor).  
7.3. Discussion of Study Design  
7.3.1. Rationale for Study Population  
Patients with pain associated with OA of either the knee as  defined by [CONTACT_569542] (for example, 
hypertension) that are well controlled are eligible .  In general , this p opulation tolerates IA 
injections of commercially available corticosteroids ( Habib 2009).  In prior clinical studies of 
FX006 in this population, single injections of up to 60 mg of FX006 were well tolerated.  
7.3.2. Rationale for Dos e Selection  
The US Food and Drug Administration (FDA ) approved dose of FX006 as an approved 
treatment for pain associated with OA of the knee is 32 mg ; therefore , this dose was selected for 
further study in investigational uses. 
7.3.3. Rationale for Study Design  
The current trial design  is substantially similar to synovitis  studies previously c onducted in OA 
of the knee  (Gait et al , 2016;  O’Neill et al, 2016) . The  design applied in this protocol has proved 
reliable for evaluating changes in synovitis and synovial tissue volume .  
7.3.4. Rationale for Study Parameters  
Synovial volume and structural changes in various tissues (bone, cartilage, meniscus) and change 
in contrast enhancement of tissues  other than synovium evaluated on the basis of MRI results 
directly support  the assessment of the effect on synovial inflammation  following IA 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 25 of 54  administration of  FX006,  and the  analyses are substantially similar to those conducted for 
assessment of synoviti s and changes in synovial tissue volume . 
The clinical safety parameters to be assessed (adverse events, physical examinations, index knee  
examinations, vital signs, and clinical laboratory evaluations) are standard safety and tolerability 
assessments and support the clinical monitoring necessary based on the safety  profile for FX006.  
7.3.5. Rationale for Control Type  
Not applicable.  This is a sing le arm ope n-label study.  
7.4. Selection of Study Population  
7.4.1. Number of Patient s 
Approximately [ADDRESS_746686] fulfill the following criteria:  
1. Written consent to participate in the study  
2. Male or female ≥  40 years of age  
3. Body mass index (BMI) ≤ 40 kg/m2 
4. Ambulatory and in good general health  
5. Willing and able to comply with the study procedures and visit schedules and able to follow 
verbal and written instructions  
6. Willing  to abstain from use of the following protocol -restricted medications during the study : 
• Topi[INVESTIGATOR_569505] s (from 5 days prior to Pre -treatment  MRI through Week 6, and 
again  from 5 days prior to Week 24  MRI ) 
• Intravenous (IV), intramuscular (IM) and oral corticosteroids (Note: inhaled, intranasal , 
and topi[INVESTIGATOR_88900])  
• IA corticosteroids in any joint  (other than the study medication)  
• Any IA intervention in the index knee including aspi[INVESTIGATOR_569512], including viscosupplementation (hyaluronic acid)  
• Any investigational drug, device or biologic  
• Immunomodulators, immunosuppressives, or chemotherapeutic agents  
• Live or attenuated vaccines  
7. Symptoms consistent  with OA of the index knee for ≥  6 months prior to Screening (patient 
self-report is acceptable)  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 26 of 54  8. Currently meets ACR Criteria (clinical and radiological) for OA ( Altman et al, 19 89) as 
follows:  
• Knee pain  
• at least 1 of the following:  
o Age > 50 years  
o Stiffness < 30 minutes  
o Crepi[INVESTIGATOR_72831]  
• Osteophytes (as determined by [CONTACT_569534] X -ray obtained at 
Screening ) 
9. Kellgren -Lawrence (K -L) Grade 2 or 3 in the index knee based on X -ray performed during 
Screening ( centrally  read)  
a) Grade 2: definite osteophytes and possible narrowing of joint space  
b) Grade 3: moderate multiple osteophytes, definite narrowing of joint space and some 
sclerosis and possible deformity of bone ends  
10. WOMAC A total sum score of ≥ 6 at Screening and Baseline/Day [ADDRESS_746687] mon th (as reported by [CONTACT_102])   
12. If bilateral OA exists, pain in the contralateral knee must be less than pain in the index knee 
as reported by [CONTACT_102]; if pain is equal, index knee will be identified based on knee with 
highest level of inflammation as determined by [CONTACT_2207]  
13. Sexual ly active males and females of child -bearing potential (defined as not surgically sterile 
or post -menopausal [defined as 12 consecutive months with no menses without an alternative 
medical cause] for at least 1 year as documented in medical history) agree to use one of the 
following highly effective methods  of contraception: abstinence; oral, injected, or implanted 
hormonal methods of contraception; intrauterine device or intrauterine system; condom or 
occlusive cap (diaphragm or cervical/vault caps) with s permicidal 
foam/gel/film/cream/suppository; or monogamous intercourse with a partner who is 
surgically sterile (post- vasectomy, post -hysterectomy, or tubal ligation) . Such contraceptive 
measures should be used throughout the duration of the study.  
7.4.3. Exclusio n Criteria  
Patients fulfilling at least one of the following criteria may not be included in the study:  
Disease -related criteria  
1. Any inflammatory arthritis including r eactive arthritis, rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease , gout , 
or secondary OA from gout  
2. History of infection  or crystal disease in the index knee joint   
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 27 of 54  3. Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of 
Screening .  
Previous or concomitant treatment -related criteria  
4. Presence of surgical hardware or other foreign body in the index knee  
5. Surgery or  arthroscop y of the  index knee within 12 months of Screening 
6. IA corticosteroid (investigational or marketed) in any joint  within 3 months of Screening   
7. IA treatment of the index knee with  hyaluronic acid (investigational or marketed) within 6 
months of Screening   
8. IV or IM corticosteroids (investigational or marketed) within 3 months of Screening 
9. Oral corticosteroids (investigational or marketed) within 1 month of Screening 
10. Any other IA drug/biologic in the index knee  within 6 months of Screening or 5 half -lives 
(whichever is longer) (e.g.,  platelet rich plasma (PRP) injection, stem cells, prolothera py, and 
amniotic fluid injection)  
11. Prior administration of FX00 6 (Zilretta®) 
12. Planned/anticipated surgery of the index knee during the study period  
Patient- related criteria  
13. Suspected  hypersensitivity to any form of triamcinolone  
14. History of sarcoidosis or amyloi dosis  
15. Active or history of malignancy within the last 5 years, with the exception of  resected basal 
cell carcinoma, squamous cell carcinoma of the skin, or effectively managed cervical 
carcinoma  
16. History or evidence of  active or latent  systemic fungal or mycobacterial infection (including 
tuberculosis), or of ocular herpes simplex  
17. Any bacterial or viral  infection requiring IV antibiotics within 4 weeks of Screening or oral 
antibiotics within 2 weeks of Screening 
18. History of osteomyelitis  in the index leg at any time, or of other areas within 5 years  
19. Laboratory evidence of infection with hum an immunodeficiency virus (HIV), positive test 
for hepatitis B surface antigen (H bsAg) , or positive serology for hepatitis C virus (HCV) 
with positive test for HCV Ribonucleic Acid ( RNA )  
20. Any electrocardiogram (ECG) abnormality judged clinically significan t by [CONTACT_737]  
21. A medical history suggesting the patient  will or is  likely to require a course of  parenteral or 
oral corticosteroids during the study period  
22. eGFR results < 40 mL/minute  (reported as Creatin ine Clearance)  
23. Any contraindication to MRI Scanning (e.g., presence of certain ferromagnetic foreign 
bodies or electronic devices including most cardiac pacemakers , claustrophobia )  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746688]  
25. History of or active Cushing’s syndrom e 
26. Active substance abuse (drugs or alcohol)  or history of substance abuse within [ADDRESS_746689]  
28. Females  who are pregnant or nursing or plan to become pregnant during the study; men who 
plan to conceive during the study  
29. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 5 years 
of Screening  
30. Has received a live or live attenuated vaccine within 3 months of Screening  
31. Use of any other investigational drug , biolog ic, or device within 3 months  of Screening  
32. Any other clinically significant acute or chronic medical conditions (e.g., bleeding disorder) 
that, in the judgment of the Investigator, would preclude the use of an IA corticosteroid or 
that could compromise pa tient safety, limit the patient’s ability to complete the study, and/or 
compromise the objectives of the s tudy.  
7.4.4. Screen Failures  
Minimal data for patients who fail screening such as demographic information and the reason for 
screen failure will be collected . 
Patients that fail to meet eligibility criteria may be re -screened at the discretion of the Medical 
Monitor.  The Medical Monitor will clearly document the rationale for any re -screening decision.  
Patients that are allowed to  re-screen will be assigned a new screening number, re -consented and 
may have screening assessments repeated if necessary.   
7.5. Treatment Administered  
7.5.1. Study Medication  Treatment Arm (s) 
Investigational Medicinal Product Arm:  
• FX006: an extended- release formulation of TA  in 75:[ADDRESS_746690](s)  
FX006 is supplied as a sterile, white to off white powder in a single unit dose 5 mL vial with a 
butyl rubber stopper, aluminum seal and plastic cap.  FX006 is reconstituted in diluent 
containing an isotonic, sterile aqueous solution of sodium chloride (NaCl; 0.9% w/w), 
carboxymethylcellulose sodium (CMC; 0.5% w/w) and polysorbate -80 (0.1 % w/w) to form a 
suspension prior to IA injectio n.  Diluent will be supplied as a sterile liquid in a 5 mL vial with a 
butyl rubber stopper, aluminum seal and plastic cap.  FX006 will be reconstituted in 5.0 mL of 
diluent to form a suspension immediately  prior to IA injection.  FX006 will be administered as a 
single 5 mL IA injection.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746691] 
requirements, local institutional policies, and applicable law. Before delegating this activity, the 
Principal I nvestigator should also ensure that the delegate is trained on and understands the 
requirements of the protocol.  
The p ackaged kits  of FX006 will be stored in a secure area and will be stored refrigerated at 2 to 
8 °C. 
7.5.4. Packaging and Labeling of Study Medication  
The packaged kit of FX006 will contain one (1) vial of FX006, one (1) vial of Diluent, and a vial 
adapter.  The F X006 and diluent vials will be labelled with their respective unique lot numbers 
within the packaged kit, which will be affixed with its own label and kit number.   
7.5.5. Return of Study Medication 
All study medications (packaged kits/used and unused vials) will be returned to the  drug supply 
distribution center .  Return of study medications will be properly documented. 
7.5.6. Method of Assigning Patient s to Treatment Groups  
This is a single arm open -label study. All patients will receive a single IA injection of FX006 
32 mg . 
7.5.7. Blinding  
This is an open- label study.  
7.5.8. Study Drug  Administration  Procedure  
IA injections of study drug  will be performed by [CONTACT_538726].  The injector may choose 
the position of the knee ( e.g., extended or flexed), the approach for t he injection ( e.g., medial or 
lateral) an d the numbing agent to be used based on standard of care. Sterile technique should be 
used.   
Prior to injection, the index knee should be thoroughly cleansed using a bactericidal solution.  
The index knee will be a spi[INVESTIGATOR_569507].  
Following attempted aspi[INVESTIGATOR_1516], 5 mL of the reconstituted FX006 will be injected into the 
synovial space.  Refer to the Pharmacy Binder  for detailed instructions on how to prepare 
FX006.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746692] related issues relating to reconstitution 
or administration of FX006 (e.g. inability to achieve an appropriate suspension, inability to 
administer the full dose due to clogging of the needle) and report the occurrence to the Site 
Monitor, as detailed in the Pharmacy Binder.  
  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746693] to physical activity throughout the duration of the  study.  
If the patient has an immediate reaction (e.g., tenderness, increased pain, swelling, effusion, 
decreas ed mobility of the index joint)  the patient should be treated according to local clinical 
guidelines and physician experience. Refer to protocol S ection 8.4.3. 
7.5.9. Treatment Compliance  
Study medication will be administered by [CONTACT_538741].  Details regarding study 
medication administration will be documented in the electronic Case Report Form (eCRF).  The 
receipt, dispensation, and return/destruction of any study medication will be properly 
documented per the instructions within the Drug Tracking Module . 
If for any reason the administration of study medication is stopped before the entire volume is 
injected, the injector should document the reason for stoppi[INVESTIGATOR_569513].  
7.5.10. Removal of Patients  from Therapy or Assessments  
Each patient in this study receives study medication as a single IA injection. Therefore, 
discontinuation from treatment is not applicable. However, e ach patient may discontinue from 
the study for further assessments and study visits.  
Each patient  will be  informed of his/her right to discontinue  from the study at any time for any 
reason and without prejudice to alternative treatment.  The PI  [INVESTIGATOR_569514]  a patient  
from the study at any time if , for example, he/she considers the patient ’s health to be 
compromised by [CONTACT_538742] , or the study is prematurely terminated.  In these cases , 
the PI  [INVESTIGATOR_1318]: 
1. Attempt to arrange for a formal Early Termination Visit and complete the study assessments 
specified for the End -of-Study scheduled for Week 24.   
2. Determine whether the patient is willing to be contact[CONTACT_569543] A Es 
through Week 24  (if reason  for discontinuation is not “subject withdrew consent”) . 
3. Document patient consent in the source document for continued follow -up.  
4. Contact [CONTACT_3433] e patient as necessary (via phone or in -person) to follow ongoing or new A Es 
through Week 24  (concomitant medications associated with any AE will also be captured).  
Data collected from discontinued patients will be included in the clinical study report. Pa tients 
who discontinue from the study may be replaced at  the discretion of the Sponsor. 
7.6. Prior and Concomitant Medications and Therap ies  
During the study, all existing (prior to study entry), new, or changes in concomitant medications  
and the associated reasons for use or change will be documented and reported. 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 32 of 54  7.6.1. Allowable Medications  and Therapi[INVESTIGATOR_569515]:  
• Any treatment for a pre- existing condition or for an AE, including the study indication (e.g., 
analgesic medications), that is not listed below as restricted  
• Physical therapy for index knee  
• Bracing of index knee  
7.6.2. Restricted Medications  
Per the exclusion criteria , a patient is not eligible for this study  if he/she has received any of the 
indicated treatments  within the specified windows  detailed in the  Exclusion criteria 
(Section  7.4.3).  In addition, the  following  medications should not be taken or used from the time 
of obtaining consent to the End of Study visit :   
• Topi[INVESTIGATOR_569505] s (from 5 days prior to Pre -treatment  MRI through Week 6, and a gain 
from 5 days prior to Week 24 MRI ) 
• IV, IM , or oral corticosteroids   
• IA corticosteroids in any joint   
• Any IA intervention in index  knee including aspi[INVESTIGATOR_569516], including viscosupplementation (hyaluronic acid)  
• Any investigational drug, device or biologic  
• Immunomodulators, immunosuppressives, or chemotherapeutic agents  
• Live or a ttenuated vaccines  
7.7. Study Variables 
7.7.1. Safety Variables   
Safety and tolerability will be evaluated based on A Es spontaneously reported by [CONTACT_569544]: physical 
examinations, index knee  assessments, vital signs, and clinical laboratory evaluations.  
7.7.2. Imaging Variables  
Synovial volume and s tructural changes in various tissues (bone, cartilage, meniscus) and change 
in contrast enhancement of tissues other than synovium  will be  evaluated on the basis of MRI  by 
a central imaging vendor .  
7.7.3. Efficacy Variables  
Efficacy will be evaluated on the basi s of the results of the WOMAC Osteoarthritis Index  LK 
3.1, 5- point scale): pain, stiffness and function domains independently and collectively ( Bellamy 
et al,  1988), the KOOS QOL  Subscale ( http://www .koos.nu/ ) and a set of questions exploring 
pain and stiffness  of the knee .  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 33 of 54  7.7.4. Biomarker Variables  
Synovial fluid samples will be preserved for a maximum of 5 years for potential future analyses 
of biomarkers that may contribute to the pathogenesis of OA and/or be associated with 
responsiveness to FX006 treatment. No genomic analyses (gene sequencing studies) will be 
performed using these samples. Patients will be able to withdraw consent throughout the duration 
of storage. Once analysis has begun, consent will no longe r be able to be withdrawn. 
Whole blood samples will be taken from patients at Baseline/Day 1 . Total RNA will be isolated 
from these samples for analysis of messenger RNA (mRNA) levels of the pro -inflammatory 
cytokine IL -1β.  The expression of baseline IL -1β among patients will be compared to several 
other parameters, such as i ndex knee X -rays and MRI images, with the goal of determining if 
baseline mRNA IL -1β expression contributes to the pathogenesis of OA and/or is  associated with 
responsiveness to FX006 treatment.   
7.8. Schedule of Study Assessments  
A summary of the schedule of study assessments is provided  in Table 1 .  Refer to Section  7.9 for 
details of each assessment.   
 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 34 of 54  Table 1:  Schedule of Study Assessments  
Procedures  Screening1 
 Pre-
Treatment2 Baseline  / 
Day 1  Week  
63 Week  
123,4 Week  
183,4 Week 24  /  
End of Study3 
Informed consent  X5       
Inclusion/Exclusion Review  X  X6     
Medical History/Update  X  X6     
OA Medical History/Update  X  X6     
Prior Treatment & Medications7 X  X6     
Physical Examination X      X 
Index Knee X -ray8 X       
Index Knee Assessment9  X  X6 X   X 
Ultrasound examination of index knee10  X      
MRI with contrast of index knee11  X  X   X 
12-Lead ECG  X       
Vital Signs  X  X6    X 
Height  X       
Weight and BMI  X      X 
Hematology & Chemistry12 X      X 
HIV, Hepatitis B/ C12 X       
IL-1β mRNA levels12   X6     
eGFR12,[ADDRESS_746694]  14   X6    X 
WOMAC15  X  X6 X X X X 
Supplemental pain  and stiffness  questionnaire15   X6 X   X 
KOOS QOL15   X6 X   X 
Index knee aspi[INVESTIGATOR_569517]8   X6     
Treatment administration    X     
AEs & ConMeds  [ADDRESS_746695] be within 10 days of Baseline/Day 1  and once eligibility is confirmed.  
3 Visit should be conducted within +/ - [ADDRESS_746696] any medications received within 30 days prior to the Screening visit  
8 Standing, fixed flexion PA view, weight bearing X -ray of the index knee will be taken using a standardized knee positioning device. The 
Screening X -ray will be read centrally for KL grade, the presence of osteophytes and the measurement of joint space width.   
9 Index knee will be as sessed for tenderness, heat/redness, swelling, effusion, and Baker’s cyst. New clinically significant findings or findings th at 
worsen from the patient’s baseline condition should be recorded as AEs.  
[ADDRESS_746697] be performed w ithin -10 days prior to Baseline/Day [ADDRESS_746698] be performed within - 10 days prior to  Baseline/Day 1 and +/ - 7 days of Weeks 6 and 24 and only if eGFR results are ≥  40 mL/min 
per the central laboratory. MRI images should follow the vendor specific knee sequences as detailed in MRI Acquisition Manual.   
[ADDRESS_746699] to be performed via central laboratory at Screening;  urine pregnancy 
test to be performed locally at Baseline/Day 1 and results available prior to dosing.  
15 Patient questionnaires to be completed prior to all other assessments  
16 AEs and Concomitant Medications will be captured from Day 1 (from start of study drug administratio n) to Week 24/Final Visit  
17 SAEs will be recorded from Informed Consent to the end of participation in the study or Week 24/Final Visit  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 35 of 54  7.9. Study Procedures  
7.9.1. Informed Consent  
Prior to initiation of any study related procedures, patients will be informed about the nature and 
purpose of the study, participation and termination conditions, and risks and benefits.  Patients 
will be given the opportunity to ask questions of site per sonnel and to discuss with family or 
friends if they wish.  After a patient has had ample opportunity to consider the information 
provided, they will be asked to sign the study’s informed consent form to participate in the study.  
7.9.2. Review of E ligibility, M edical H istory, P rior T reatment , and M edications  
Eligibility criteria (inclusion and exclusion criteria), medical history (including OA history), and 
prior treatment and medications are reviewed during screening and again at Day 1.  
OA medical history includes ACR diagnosis details, OA diagnosis date (if available), number of 
days with pain in both knees in the last month, and previous IA steroid or hyaluronic injections . 
7.9.3. Physical Examination  
The physical exam will assess the followin g body systems:  
1. General Appearance  
2. Skin 
3. Lymphatics  
4. HEENT (head, ears, eyes, nose, throat)  
5. Cardiovascular  
6. Respi[INVESTIGATOR_696]  
7. Abdominal  
8. Musculoskeletal  
9. Neurological  
Any clinically significant findings , outside of the typi[INVESTIGATOR_538710], must be documented in 
the source and added to the medical history if found at Screening or recorded as an AE if new or 
worsened from pre-dosing on Day 1.    
7.9.4. Index Knee X -ray 
A diagnostic quality X -ray of the index knee is required (standing, fixed flexion PA view;  
weight -bearing ; use of standardized knee positioning device is required) at Screening. The X -ray 
will be  sent to the central imaging vendor for K -L grading , the presence of osteophytes (both 
required for eligibility) , and joint space width. An image acquisition manual will be distributed 
to sites with simple instructions for radioanatomic  positioning for reliable grading.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 36 of 54  7.9.5. Index Knee  Ultrasound  
A diagnostic quality ultrasound of the index knee is required within - 10 days prior to Day 
1/Basel ine. The ultrasound will be read locally  for inflammation .  Please refer to Schedule of 
Study Assessments for specific timing requirements.  
[IP_ADDRESS]. Machine C apabilities  
The machines used in the study should be able to distinguish the edge of proliferated synovium 
from the surrounding periarticular fat.  For the patient with a higher BMI, a lower frequency 
transducer capability e.g. , 7.5- 10 MHz should be available, with a normal scanning frequency 
expected between 10MHz and 15 MHz being optimal.  All scanning will be performed with a 
linear transducer.  
[IP_ADDRESS]. Scanning  Method  
The knee will be scanned in a semi -flexed position, approximately [ADDRESS_746700] any fluid. Once 
the anterior and posterior surfaces are gently touching, a total measurement of synovial thickness 
is made using the machine’s built- in electronic callipers. Thi s measurement is recorded in mm. 
This is then divided by [CONTACT_569545].  The use of 
≥ 2mm thickening synovium will define abnormal synovial thickening.  
[IP_ADDRESS]. Image C apture  
The best representative image should be captured, co rrectly labelled (left or right knee) , and 
saved in both a longitudinal and transverse view. The same longitudinal image used to show the 
electronic callipers will be saved. The thickness of the synovium will be d isplayed on the screen 
in mm. For further e xternal verification, a [ADDRESS_746701]  agent  of the index knee is required 
within 10 days prior to Day 1/Baseline, and then again at Week 6 and Week 24 (+/ - 7 days) .  
Once eligibility is confirmed, a pre -treatment MRI will be obtained and submitted to the central 
imaging facility to confirm image quality. Documenta tion of  a quality MRI is needed prior to 
Day 1 /Baseline .  If the initial pre -treatment MRI fails quality control ( QC), another MRI will 
need to be completed prior to Day 1/Baseline but at least 3- [ADDRESS_746702] agent has washed out.  
All subsequent images (Week 6 and 24) will need to be completed on the same machine  with the 
same coil and software as the Pre -treatment image and will need to be submitted to the central 
imaging vendor  to confirm image quality.  If the image does not pass QC, another MRI will need 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 37 of 54  to be c ompleted within the +/-  [ADDRESS_746703] agent has washed out.  
An MRI image acquisition manual  will be distributed to sites with  detailed technical  instructions  
and specifications  for imaging sequences, imaging coil and Field of View (FOV) positions. 
The MRI will be analyzed centrally for the primary endpoint as well as the secondary and 
exploratory endpoints based on imaging.  
7.9.7. Index Knee  Assessment  
The index kne e assessment will be performed by [CONTACT_569546] . The index knee  will be assessed fo r tenderness, 
heat/redness, swelling, effusion, and  Baker’s cyst .  If there is a clinically significant finding 
outside of the patient’s typi[INVESTIGATOR_569518]  1 Visit (pre -injection) , add to 
the Medical History.  At time points post -injection , if there are n ew clinically significant findings 
or findings that worsen for the patient’s baseline condition, record as A Es. 
7.9.8. 12-lead ECG  
At Screening, a 12 -lead ECG will be obtained in  the supi[INVESTIGATOR_2547]. Measures of heart rate, PR  
interval, RR interval, QT  interval, QT interval corrected for heart rate ( QTc) (corrected for 
Bazett’s or Fridericia’s) interval , and QRS duration will be obtained.  ECGs will be locally read 
and a copy of each recording will be kept with  the patient’s so urce documentation. If any 
abnormality is determined to be clinically significant by [CONTACT_737], the patient would be a 
screen failure.   
7.9.9. Vital Signs  
Vital signs are to be taken at the days indicated in  the Schedu le of Study Assessments . The 
following measurements will be taken: sitting blood pressure, h eart rate, respi[INVESTIGATOR_1487] , and 
temperature.   
7.9.10. Height, Weight , and BMI D etermination  
Height and weight are to be taken at the days indicated in  the Schedule of Study Assessments .  
Height will be measured in centimeters  (cm)  or inches. Weight w ill be measured in kilograms or 
pounds. BMI will be calculated using the formulas in Table 2  (reference: www.cdc.gov ): 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 38 of 54  Table 2:  BMI Calculations  
Measurement Units  Formula and Calculation  
Kilograms and meters 
(or centimeters)  Formula: weight (kg) / [height (m)]2 
With the metric system, the formula for BMI is weight in kilograms 
divided by [CONTACT_55739].  
If, as common, height is measured in centimeters, divide height in 
centimeters by 100 to obtain height in meters.  
Example: Weight = 68 kg, Height = 165 cm (1.65 m)  
Calculation: 68 ÷ (1.65)2 = 24.98 
Pounds and inches  Formula: weight (lb) / [height (in)]2 x 703  
Calculate BMI by [CONTACT_538748] (lbs) by [CONTACT_538749] 
(in) squared and multiplying by a conversion factor of 703.  
Example: Weight = 150 lbs, Height = 5’ 5” (65”) 
Calculation: [150 ÷ (65)2] x 703 = 24.96 
7.9.11. Synovial Fluid Aspi[INVESTIGATOR_569519] 1 prior to study medication administration. The injector/aspi[INVESTIGATOR_569520].  The volume of the 
synovial fluid obtained will be recorded in the eCRF. If no synovial fluid is obtained then 0 mLs 
should be recorded.  Procedures for sample collection, handling, storage , and shipment will be 
described in the Central Laborat ory Manual.  The synovial fluid samples  will be preserved for 
potential future analyses of biomarkers that may contribute to the pathogenesis of OA and/or be 
associated with responsiveness to FX006 treatment . 
7.9.12. Central Clinical Laboratory Evaluations  
Blood s amples will be taken at  the days indicated in the Schedule of Study Assessments .  The 
specific laboratory panels to be run can be found in Table 3 .  Follow the Central Laboratory 
Manual for detailed sample collection, handling, storage, and shippi[INVESTIGATOR_3931]. 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 39 of 54  Table 3:  Clinical Laboratory Panel  
Hematology  Clinical Chemistry  
Hemoglobin  Sodium  
Hematocrit  Potassium  
Erythrocyte count ( red blood cells [ RBC ]) Bicarbonate  
Mean cell volume  Chloride  
Leukocytes ( white blood cells [ WBC ])  Calcium   
Absolute counts of:  Total bilirubin  
• Neutrophils  Alkaline phosphatase  
• Lymphocytes  Alanine aminotransferase  
• Monocytes  Aspartate aminotransferase  
• Eosinophils  Blood urea nitrogen  
• Basophils  Creatinine  
• Platelets  Uric acid  
 Glucose  
Infectious diseases   Total protein  
Hepatitis B Surface Antigen  Albumin  
Hepatitis C Virus Antibody1  
HIV2  
  
Other    
IL-1β mRNA levels   
eGFR   
Pregnancy tests ( females  of child -bearing potential only)  
Serum : submitted to and performed by [CONTACT_538750]: test provided by [CONTACT_538751]  
1. Patients positive for HCV Antibody will have reflex testing for circulating HCV RNA.  
2. HIV screening will use a current 4th generation test for both antibody and viral antigen.  
7.9.13. Patient Questionnair es 
The following questionnaires will be completed by [CONTACT_569547] 1.  
• WOMAC® LK 3.1  
• KOOS -  Quality of Life Subscale (Q1 -Q4) 
• Supplemental Pain and Stiffness Questions  
7.9.14. Treatment Administration  
At Day 1, and after completion of all required assessments, the following will occur: 
• Study medication will be prepared by [CONTACT_32335]/coordinator .  Refer to the Pharmacy 
Binder for FX006 dose preparation instructions.  
• Synovial fluid will be aspi[INVESTIGATOR_569521] (refer to Section  7.9.11 for more details of the synovial fluid aspi[INVESTIGATOR_1516]). 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 40 of 54  • The injector /aspi[INVESTIGATOR_569522] ( refer to  
Section  7.5.8 for instructions).   
7.9.15. Review of A dverse E vents and C oncomitant M edicat ions 
Subjects will be monitored for adverse events from signing of informed consent through the end 
of their participation in the study. Refer to Section  8.4.[ADDRESS_746704] ing allowed and restricted 
concomitant medication s and therapi[INVESTIGATOR_014] . 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 41 of 54  8. ADVERSE EVENTS  
Subjects will be monitored for adv erse events from signing of informed consent through the end 
of their participation in the study.  
Between the signing of the informed consent and initiation of study medication, only serious 
adverse events will be recorded on the eCRF. Following the start  of study drug administration, 
all treatment- emergent a dverse events , including serious adverse events , will be collected 
through the Final Visit . Results of clinical safety assessments are to be recorded in the patient’s 
medical records and transcribed to the appropriate eCRF, including the AE eCRF for clinically 
significant findings.  
 
8.1. Definitions 
Adverse Event  (AE ): An AE is any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product a nd that does not necessarily have a 
causal relationship with this treatment.  An AE can therefore be :   
• Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal (i nvestigational) 
product, whether or not related to the medicinal (investigational) product.  
• Any clinically significant abnormality found on an ECG, laboratory test , or physical 
examination.  
• Any worsening (i.e., any clinical significant adverse change in f requency and/or 
intensity) of a preexisting condition,  which is temporally associated with the use of the 
medicinal (investigational) product  
Serious Adverse Event (SAE ): An S AE is any untoward medical occurrence that at any dose:  
• Results in death, 
• Is life -threatening,  
o “Life -threatening” refers to an event in which the patient was at substantial risk of 
death at the time of the event; it does not refer to an event which hypothetically might 
have caused death if it were more severe.   
• Requires inpatient hospi[INVESTIGATOR_1081], 
o Note:  Adverse events requiring hos pi[INVESTIGATOR_569523] 24 hours in 
duration do not meet this criterion. A planned hospi[INVESTIGATOR_442455] a pre- existing condition that has not worsened during participation in the 
study does not meet this criterion.  
• Results  in permanent or significant disability/incapacity ; a substantial disruption of the 
patient’s ability to carry out normal life functions.  
• Is a congenital anomaly/birth defect.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 42 of 54  • Is an important medical event : event that may not be immediately life -threatenin g or 
result in death or hospi[INVESTIGATOR_569524] . 
Planned Hospi[INVESTIGATOR_059]:  
A hospi[INVESTIGATOR_569525] a therapeutic 
intervention.  If the planned hospi[INVESTIGATOR_557021], it should be 
recorded in the patient’s medical history.  However, if complications arise during the planned 
hospi[INVESTIGATOR_569526], it must be reported as an AE.  
8.2. Monitoring of Adverse Events  
At each visit , all AEs and SAEs that occur from the time of treatment and throughout a patient’s 
study participation that are  observed or reported by [CONTACT_102], will be recorded in the source 
documentation and appropriate section of the AE or SAE  eCRF .   
The Investigator is required to follow SAEs until resolution or withdrawal of consent. Resolution 
is defined as:  
• A return to  baseline for a pre -existing condition;  
• Resolved with or without residual effects;  
• The Investigator does not expect any further improvement or worsening of the event;  
• Fatal  outcome:  If an autopsy is performed on a deceased patient , the autopsy report 
should be provided to the S ponsor as soon as it is available . 
8.2.1. Monitoring of Laboratory Assessments  and other Diagnostic Tests  
The Investigator will review results of laboratory and other diagnostic tests  for clinical 
significance and consideration as an AE.  
8.3. Assessment of Adverse Events  
8.3.1. Assessment of Severity  
Each adverse event should be evaluated for severity or intensity. This is not the same as 
“serious,”  which is ba sed on patient /event outcome or action criteria usually associated with 
events that pose a threat to a patient ’s life or functioning. The severity of AEs will be  assessed 
according to the following definitions :   
• Mild :  the AE is noticeable to the patient and/or the Investigator, but does not interfere 
with routine activity.  
• Moderate:   the AE interferes with routine activity, but responds to symptomatic therapy 
or rest.  
• Severe:   the AE significantly limits the patient’s ability to perform routine activities  
despi[INVESTIGATOR_4795].  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746705] assess the relationship of any AE (including SAEs) to 
the use of the investigational product, as related  or not related , based on clinical judgment and 
using all available information, and may include consideration of the following factors:  
• Possible alternative causes of the AE, including the disease under treatment, pre -existing 
conditions, concomitant use of other drugs, and presence of environmental or genetic 
factors.  
• The temporal association between drug exposure and onset of the AE.  
• Whether the manifestations of the AE are consistent with known actions or toxicity of the 
investigational product. 
The causal relationship between the study medication and the AE will be assessed using one of 
the following categories:  
Not Related:  An AE is not associated with study medication if:  
• Temporal relationship is lacking (e.g., the event did not occur within a reasonable 
time frame following administration of the study medication); or   
• Other causative factors more likely explain the event (e.g., a pre- existing condition, 
other concomitant treatmen ts). 
Related:  An AE is attributed to the study medication if:  
• There is a positive temporal relations hip (e.g., the event occurred within a reasonable 
time frame following administration of study medication ); and 
• The AE is more likely explained by [CONTACT_226189] 
(i.e., the AE shows a pattern consistent with previous know ledge of the 
investigational product or the class of the investigational product) .  
8.4. Recording  of Adverse Events 
All AEs, regardless of seriousness, severity, or causal relationship to study medication, will be 
recorded on the AE page of the eCRF.   
If discernible at the time of completing an AE eCRF, a specific disease or syndrome rather than 
individual associated s igns and symptoms should be identified by [CONTACT_569548] .  However, if an observed or reported sign, symptom, or clinically 
significant laboratory anomaly is not considered by [CONTACT_63033] a component of a 
specific disease or syndrome, then it should be recorded as a separate AE on the appropriate AE 
eCRF.  
8.4.1. Reporting of Serious Adverse Events  
When an SAE occurs, the Investigator or designee, must log into the electronic data capture 
(EDC) system and complet e the SAE report form within 24 hours of becoming aware of the 
SAE. The EDC system will notify the Medical Monitor and other appropriate study personnel of 
the SAE.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746706] be reported to the Sponsor  within 24 hours of 
receipt by [CONTACT_569549].   
All SAEs that occur at your site should, in addition, be reported by [CONTACT_569550]/EC without undue delay, if applica ble according to IRB/EC requirements.  
During the conduct of the study, the Sponsor will provide expedited safety reports ( AEs 
classified as serious, unexpected and related to study medication ) to the investigative sites .  If 
this occurs, the investigative site must report the information to their IRB per local guidelines  
(may be submitted by [CONTACT_569551] a central IRB) . 
8.4.2. Safety Monitoring Roles  
The site personnel  will carefully monitor each patient throughout the study for possi ble AEs.  All 
AEs will be reviewed and assessed by [CONTACT_737].    
The Sponsor  must promptly review all information relevant to the safety of an investigational 
new product received from any source  including AE data individually and in aggregate 
throughout the course of the study .   
Investigators will receive prompt notification of any adverse experience associated with the use 
of the study medication that is both serious and unexpected, or any finding that suggests a 
significant risk for patients. The  Investigator will promptly inform the IRB/EC of the notification 
and insert the notification in the Investigator’s Regulatory Binder in accordance with local 
regulations.  
The medical monitor and the Sponsor will review the study’s safety data approximately on a 
quarterly basis, in order to identify potential safety issues/trends that may not be apparent 
through individual AE reporting.  If systematic review identifies a concern, the Sponsor will take 
steps to address the issues including, but not limited to, modifying the protocol or Informed 
Consent, and/or notifying investigator s, authorities and IRB/ECs.   
8.4.3. Clinical Management of Index Knee  Related  Events  
If the patient has an immediate reaction following administration of study medication or returns 
to the clinic with an acute exacerbation (e.g., tenderness, increased pain, swelling, effusion, 
decreased mobility of the index knee ), the patient should be treat ed according to local clinical 
guidelines and physician experience.   
If the index knee  is aspi[INVESTIGATOR_569527], 
the volume of synovial fluid aspi[INVESTIGATOR_538715], synovial fluid should be (1) 
cultured, (2) evaluated for presence of crystals and (3) assessed for white cell count at a local 
laboratory, and the results should be documented.   
Any event that is a change from the patient’s baseline status (new or worsening case) should be 
reported  as an AE and those meeting the definition of serious  must be reported in accordance 
with Section  8.4. 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746707] continue to 
follow the pregnancy until the completion of the pregnancy , including the outcome and t he 
condition of the newborn  (if applicable) .  If not all information on the Pregnancy Report Form is 
available at the time of the initial report, follow -up reports should be provided to the Sponsor in a 
timely manner.  Additional subsequent follow -up is not needed when a newborn baby [CONTACT_442473].  
 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 46 of 54  9. STATISTICAL CONSIDERATIONS  
9.1. Statistical and Analytical Plans  
Key aspects of the proposed statistical analyses are summarized below.  A comprehensive 
Statistical A nalysis P lan will be written and approved prior to database lock for this study.  If, 
after the study has  been completed , changes are made to the statistical analysis plan referenced 
below, these deviations to the plan will be listed in the Clinical Study Report (CSR) , along with 
an explanation as to why they occurred.  
9.1.1. Interim Analysis  
Once all enrolled patients in the Synovitis Imaging Population have completed the Week 6 visit 
the mean standardized change from baseline at 6 weeks in synovial volume  (the primary 
endpoint) and other efficacy measures , will be analyzed . Safety analyses may be included and 
will be detailed in the SAP. Full results of this interim analysis will be presented to the Sponsor.   
9.1.2. Final Analyses  
Once all enrolled patients have completed the Week [ADDRESS_746708] -hoc, exploratory 
analyses, may also be performed to further understand and elucidate study results ; these  analyses 
will be clearly identified as such in the CSR.  
9.2. General Considerations and Methods  
Data collected in this study will be presented using summary tables, figures, and data listings.  
Continuous variables will be summarized using descriptive statistics, including  the mean, 
median, standar d deviation, minimum and maximum .  Categorical variables will be summarized 
by [CONTACT_22977].  CIs may also be provided.  Figures will be used to support the 
presentation of certain data.  Sensitivity analyses may be performed to examine the effect of 
missing data, as well as the effect of  any baseline imbalance.  
All CIs, statistical tests, and resulting p values will be reported as 2 -sided.  Significance will be 
assessed at α = 0.05 level and the significance level will not be adjusted for the secondary 
endpoint analyses.  
9.2.1. Analysis Populations  
Complete details of the statistical analys is will be specified in the SAP.  Four  analysis 
populations are planned for this study as follows:  
• The Safety Population will include all patients who receive stu dy drug. The Safety 
Population will be used to assess safety and tolerability.  
• The Synovitis Imaging Population will include all patients from the Safety 
Population, who have a pre -treatment synovi al volume measurement of greater than 
[ADDRESS_746709] no major protocol deviations and/or imaging variations 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 47 of 54  (i.e. change i n coil, machine or software) deemed to potentially impact the imaging 
analysis.  
• The Imaging Population will include all patients from the Safety Population, who 
have quality MRI data available for pre -treatment  and at least one post baseline 
timepoint and  with no major protocol deviations  and/or imaging variations (i.e ., 
change in coil, machine or software)  deemed to potentially impact the imaging 
analysis.  
• The Efficacy Population will include all patients from the Safety Population, who 
have at least one post -Baseline WOMAC or KOOS  assessment . 
9.2.2. Study Data  
Study data identified in this protocol are collected, and source verified, on electronic Case 
Record Forms (eCRF) at sites completing the study.  All study data will be formulated into data 
sets to provide  transparency, traceability, and integrity of trial analysis results from collection 
source.  
9.2.3. Study  Variables for Assessment  
Please refer to Section  7.7 for study variables.  
9.2.4. Sub- Groups and Covariates  
Sub- groups may be defined and explored and will be documented in the Statistical Analysis 
Plan.  
9.3. Determination of Sample Size 
Approximately  100 patients  will be enrolled to ensure a minimum of 70 evaluable Synovitis 
Imaging patients, as defined by [CONTACT_094]- treatment MRI synovi al volume measurement of greater than 
3000 mm3 of gadolinium enhancement as determined by [CONTACT_569533], with  
quality Pretreatment and Week 6 MRI s. Previous trials had similar sample sizes  (Gait et al., 
2016)  (O’Neill et al. , 2016) .  
9.4. General Statistical Methods  
9.4.1. Demographics and Baseline  Characteristics  
Demographic and baseline characteristics will be listed by [CONTACT_569552] , and will be 
summarized.  Frequencies and proportions will be presented for the categorical variables and 
descriptive statistics will be presented for continuous variables.  
9.4.2. Exposure  
Treatment exposure will be listed by  [CONTACT_569553].  
9.4.3. Efficacy Analyses  
Primary efficacy endpoint:  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 48 of 54  • Mean standardized change from baseline at 6 weeks  in synovial volume     
Secondary efficacy endpoints:  
• Mean absolute change (mm3) from baseline at 6  weeks in synovial volume  
• Mean standardized change from basel ine at 24 weeks in synovial volume     
• Mean absolute change (mm3) from baseline at 24 weeks in synovial volume     
Analysis of additional secondary and exploratory endpoints will be defined in the SAP.  
9.4.4. Safety Analyses  
[IP_ADDRESS]. Analysis of Adverse Events  
AEs will be c oded using MedDRA.  Incidences (number and percent) of TEAEs ; (those events 
that started after dosing or worsened after dosing) , will be presented . Additional analyses of 
incidences of TEAEs will also be presented by [CONTACT_569554] . Similar presentations will be provided f or serious AEs,  AEs leading to death, AEs 
leading to withdrawal from the study , and for AEs related to the  index knee . 
[IP_ADDRESS]. Other Safety Analyses  
Clinical laboratory data and vital sign information will be summarized as summary statistics for 
value and change from Day [ADDRESS_746710] deviation, minimum, and maximum.  
Details for the additional safety endpoints will be provided in the SAP. 
  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746711] the clinical 
study monitor  during these visits.   
The PI  [INVESTIGATOR_538717], auditor(s), Sponsor, Sponsor designee and regulatory authorities 
direct access t o relevant clinical records . No information in these records about the identity of the 
patients will leave the clinical site.  The Sponsor will maintain the confidentiality of all patient 
records.  
Source data is all information in original records and cert ified copi[INVESTIGATOR_2149], observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained in source documents 
(original records or certified copi[INVESTIGATOR_014]) . 
Independent clinical quality assurance audits may be performed at any time during or following 
completion of the Study by [CONTACT_1034], or its authorized agents, r egulatory authorities, 
Competent Authorities and/or the IRB/EC.  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 50 of 54  11. DATA HANDLING AND RE CORDKEEP ING  
11.1. Case Report Forms  
The eCRF will be supplied by [CONTACT_538766]. All study data should initially be documented in source documents 
(e.g., patient charts, notes, laboratory reports, ECG recordings, etc.) and then subsequently 
entered from the source int o the eCRF.  All eCRFs should be filled out completely by [CONTACT_538767].  The eCRF is reviewed, signed, and dated electronically by 
[CONTACT_978] . 
11.2. Study Medication  Accountability  
All study medication  required for completion of this study will be provided by [CONTACT_95346] .  Study medication will be acknowledge d upon receipt indicating shipment content and 
condition.  Damaged supplies will be replaced.  
Accurate records of all study medications  received by, dispensed from  or returned to the study 
site should be maintained per instructions in the Pharmacy Binder . 
In the event of a temperature excursion, refer to the Pharmacy Binder for instructions. 
In the event of a product complaint, complete t he Product Complaint Form located in the 
Pharmacy Binder and send to the assigned monitor or clinical manager who will coordinate with 
the Sponsor for further guidance.  
11.3. Confidentiality of Data  
Patient medical information obtained by [CONTACT_569555], and disclosure to third parties 
other than those noted below is prohibited. 
Upon the patient’s permission, medical information may be given to his or her personal 
physician or other appropriate medical personnel responsible for his or her welfare.  
Data generated by [CONTACT_538768], the Sponsor or their representative, and the IRB /EC. 
To maintain patient privacy, all eCRFs, study drug accountability records, study reports, and 
comm unications will identify the patient by [CONTACT_175225]/or by [CONTACT_51266].  The patient’s confidentiality will be maintained and will not be made publicly 
available to the extent permitted by [CONTACT_4913] . 
11.4. Retention of Records 
In accordance with [LOCATION_002] of America Code of Federal Regulations (21 CFR 312.62[c]), 
the Sponsor requires that records and documents pertaining to the conduct of this study and the 
distribution of study medications , including eCRFs, consent forms, laboratory test results  and 
medical inventory records, must be retained by [CONTACT_978]  [INVESTIGATOR_8178] [ADDRESS_746712] be kept 2 years after the investigation is 
discontinue d and the regulatory authorities are notified.  The Sponsor or their representative will 
notify the PI  [INVESTIGATOR_54070].  If local regulations are more stringent than that specified above, the 
local regulations will be adhered to.   
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page [ADDRESS_746713] be approved by [CONTACT_569556] /EC.  When the changes involved are only log istical and administrative in nature to 
the trial this may not require prior approval by [CONTACT_1201] /EC. The PI  [INVESTIGATOR_569528].  
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 52 of 54  12. PUBLICATION POLICY 
12.1. Sponsor’s Publication Policy  
Sponsor or its designee shall have the right to publish or otherwise publicly disclose the 
information contained in or related to the Study Drug, the Study Data, or other Confidential 
Information in any form without the written consent of Site, the PI  [INVESTIGATOR_569529].  Each of 
Site and PI  [INVESTIGATOR_569530], or derived from the Study Drug, the Study Data, or 
other Confidential Information. 
12.2. Site Publication  
After the Study is completed, which means that all completed eCRFs have been received by 
[CONTACT_2728], and the database has been locked at  all participating sites  and Study closeout visits have 
taken place at all participating sites, then Site shall have the right, subject to the  Health Insurance 
Portability and Accountability Act  (HIPAA ) Rules, to publish or otherwise make public data 
resulting from the conduct of the Study at the Site upon the earlier of (a)  the date of publication 
of a multi- center publicat ion coordinated by [CONTACT_569557], and (b)  the date of submission of the data resulting from the Study by [CONTACT_569558]; provided that Site shall furnish Sponsor with a copy of any proposed 
publication or release at least 90  days in advance of the proposed submission or presentation 
date.  Within this 90- day period, the Sponsor shall review such proposed publication or release to 
determine whether it contains any Confidential Informatio n (other than Study Data), or whether 
Sponsor desires to file patent applications on subject matter contained therein, and to ensure the 
accuracy of the information contained in the publication or release. Upon receiving any 
notification from Sponsor reque sting deletion of Confidential Information (other than Study 
Data), requesting correction of inaccuracies, or requesting a delay in publication of up to 90 days 
to allow the filing of patent applications before publication or release, Site shall take the 
requested action.  The parties acknowledge and agree that Site shall be solely responsible for the 
editorial content of any such publication or release.  In a manner consistent with customary 
practice, Site shall acknowledge the support and contributions of  Sponsor, if requested by 
[CONTACT_2728], in connection with the Study, in any and all publications and presentations reporting 
and data resulting from the Study.  Site and the PI  [INVESTIGATOR_569531] 
(financial or otherwise) in connection with such publications and presentations. 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 53 of 54  13. REFERENCES  
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. The American College of 
Rheumatology cri teria for the classification and reporting of osteoarthritis of the knee. Arthritis 
Rheum 1986;29:1039- 1049American Diabetes Association . Diabetes Care 2016 Jan; 
39(Supplement 1): S39- S46 
Ayral X, Pi[INVESTIGATOR_11721] E H, Woodworth TG, Mackillop N, Dougados  M. Synovitis: a potential 
predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of 
a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage. 2005 
May;13(5):361- 7.  
Bellamy N, Buchanan WW,  Goldsmith CH, Campbell J, Stitt LW.   Validation study of 
WOMAC: A health status instrument for measuring clinically important patient relevant 
outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J 
Rheumatol 1988;15(12):1833- 1840. 
Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B . Synovial tissue 
inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005 Sep;64(9):1263- 7. 
Bodick N, Lufkin J, Willwerth C, Blanks R, Inderjeeth C, Kumar A, Clayman M. FX006 
prolongs the residency of triamcinolone acetonide in the synovial tissues  of patients with knee 
osteoarthritis. Osteoarthritis Cartilage. 2013;21:(Suppl);  S144- 5. 
Bodick N, Lufkin J, Willwerth C, Kumar A, Bolognese J, Schoonmaker C, Ballal R, Hunter  D, 
Clayman, M.  An Intra -Articular, Extended -Release Formulation of Triamcinolone Acetonide 
Prolongs and Amplifies Analgesic Effect in Patients with Osteoarthritis of the Knee, A 
Randomized Clinical Trial. J Bone Joint Surg Am. 2015;97:877- 88. 
Conaghan P G, Cohen SB, Berenbaum F, Lufkin J, Johnson JR , and Bodick N. A Phase 2b trial 
of a novel extended- release microsphere formulation of triamcinolone acetonide for intra -
articular injection in knee osteoarthritis. Arthritis Rheumatol. [ADDRESS_746714] 31. 
doi:10.1002/art.[ZIP_CODE]. [Epub ahead of print]  
Creamer P, Hochberg MC.  Osteoarthritis. Lancet 1997;350(906):503–508. 
Gait AD, Hodgson R, Parkes M J, Hutchinson CE, O’Neill TW, Maricar N, et al . Synovial 
volume vs synovial measurements from dynamic contract enhanced MRI as measures of 
response in osteoarthritis. Osteoarthritis and Cartilage 2016; 24: 1392- 1398.  
Goldring SR  and Goldring MB.  Clinical aspects, pathology and pathophysiology of 
osteo arthritis. J Musculoskelet Neuronal Interact 2006;6(4):376–378. 
Habib GS.  Systemic effects of intra -articular corticosteroids. Clin Rheumatol 2009;28:749–756.  
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al .  American 
College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and 
Flexion Therapeutics, Inc.  Protocol FX00 6-2017- 014 
FX006  Version 6.0 (12 Jul y 2019)  
CONFIDENTIAL  Page 54 of 54  Pharmacologic Therapi[INVESTIGATOR_538722], Hip, and Knee. Arthritis Care Res  
(Hoboken)  2012; 64(4):465- 474. 
Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al .  EULAR 
Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: 
Report of a Task Force of the Standing Committee for International Clinical Studies Including 
Therapeutic Trials (ESCISIT).  Ann Rheum Dis 2003;62(12) :1145–1155. 
Menge TJ, Boykin RE, By[CONTACT_538772], Bushnell BD. A Comprehensive Approach to Glenohumeral 
Arthritis. So uth Med J . 2014;107(9):567- 573. 
O’Neill TW, Parkes MJ, Maricar, N, Marjanovic EJ, Hodgson R, Gait AD, et al . Synovial tissue 
volume: a treatment target in knee  osteoarthritis (OA) . Ann Rheum Dis 2016;75:84- 90. 
Sellam J and Berenbaum F . The role of synovitis in pathophysiology and clinical symptoms of 
osteoarthritis. Nat Rev Rheumatol. 2010 Nov;6(11):625- 35. 
Wenham CY  and Conaghan PG. The role of synovitis in osteoarthritis. Ther Adv Musculoskelet 
Dis. 2010 Dec;2(6):349- 59. 